Re: Leclercq et al.: Anti-tumor necrosis factor-alpha versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network (Ophthalmology. 2022;129:520-529) REPLY
| Autor: | Gelmi, M.C., Bas, Z., Malkani, K., Ganguly, A., Shields, C.L., Jager, M.J. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|